News

Xeltis Completes Key Trials for aXess Vascular Innovation

Xeltis Completes Key Trials for aXess Vascular Innovation

Xeltis Completes Patient Enrollment in Pivotal aXess Trial

Xeltis has successfully completed the patient enrollment phase of its EU Pivotal trial for the aXess device, designed to significantly improve vascular access in adults suffering from end-stage renal disease. This trial, which has enrolled 120 patients across 22 centers, represents a major step forward in providing effective treatment for hemodialysis patients.

Understanding the aXess Technology

The aXess device is a groundbreaking restorative vascular access conduit that emphasizes the natural regeneration of living vessels. This technology uniquely addresses the common challenges faced by dialysis patients, particularly the frequent need for reinterventions and the risks of complications. Early data from previous studies have been promising, showcasing a zero infection rate and exceptional performance compared to existing hemodialysis vascular access solutions.

Clinical Trial Overview

The aXess EU pivotal trial focuses on investigating the patency, safety, and overall performance of this innovative conduit. The incorporation of 120 patients in nine countries highlights the extensive reach of the trial, reflecting the growing demand for improved dialysis access solutions globally.

Insights from Investigators

Professor Loreto Gesualdo, a key Principal Investigator, expressed pride in contributing to this vital study. He emphasized the role of aXess in transforming patient outcomes, particularly by reducing the incidence of non-maturation of fistulas, which is a significant concern in hemodialysis treatment.

The Path Towards Market Approval

With expectations of primary endpoint readouts in the second quarter of the following year and market approval anticipated soon after, Xeltis is moving rapidly towards making aXess available to those in need. The recent appointment of Rob Eyers as Chief Technology Officer reinforces the company’s commitment to innovation and excellence in the medtech field.

Leadership and Vision at Xeltis

Rob Eyers brings over 30 years of experience in the cardiovascular medtech industry, previously holding significant roles at various prestigious organizations. His extensive background equips Xeltis with invaluable insights necessary for navigating regulatory pathways and advancing towards commercialization.

Innovative Potential of aXess

The Endogenous Tissue Restoration (ETR) technology incorporated in the aXess design represents a new benchmark in medical device innovation. It is engineered to regenerate a patient's own tissue, thus addressing the critical issue of treatment complications such as infections. This innovative capability positions Xeltis to lead the market in effective and sustainable hemodialysis solutions.

Future Directions for Xeltis

Xeltis is actively pursuing further patient enrollment in its US pivotal trial, demonstrating its dedication to broadening the reach and impact of the aXess vascular access conduit. The collaboration with distinguished medical professionals worldwide reflects the strength of its clinical support system.

About Xeltis

Xeltis stands at the forefront of medtech innovation, dedicated to developing transformative implants that facilitate the natural formation of lasting vascular structures. The company focuses on addressing the critical need for effective hemodialysis access grafts and cardiovascular replacements, reshaping the landscape for millions of patients in need.

Frequently Asked Questions

What is the aXess device?

The aXess device is a restorative vascular access conduit designed for patients requiring hemodialysis, focusing on the natural creation of living blood vessels.

What makes aXess different from other vascular access solutions?

aXess utilizes innovative ETR technology that allows for tissue regeneration, avoiding complications typically associated with traditional treatment options.

How many patients are involved in the aXess trial?

A total of 120 patients are participating in the EU Pivotal trial across 22 centers in multiple European countries.

What are the anticipated outcomes from the trial?

The primary endpoint readouts from the trial are expected to be revealed in the second quarter of the following year, paving the way for potential market approval soon after.

Who leads the research efforts for aXess?

The trial includes notable investigators like Professor Loreto Gesualdo and is supported by Xeltis' Chief Technology Officer, Rob Eyers, who brings extensive industry experience.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 104

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Action1's 3,688% Growth Puts Patching on Investor Maps

Updated Category News Views 87

Patch Management Finally Gets Some Respect Nothing makes a security buyer flinch faster than a machine carrying a known vulnerability for weeks, and Action1 has plainly found that nerve. The Houston-based autonomous endpoint management company says it was the fastest-growing endpoint management vendor on Deloitte's 2026 Technology Fast 500 for the second consecutive year,...

Continue Reading
Banks Face a Choice: Retreat or Fund Climate Resilience

Updated Category News Views 122

A flooded field can turn a prudent loan book into a social retreat overnight. That is the uncomfortable nerve in the Global Alliance for Banking on Values paper unveiled at COP31 in Antalya on November 19, 2026. Banks have become very practiced at mapping physical climate exposure, raising prices, tightening standards and stepping away. Fine, risk discipline matters. But...

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 117

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 9

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 84

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 22

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
Dutch Solar Homes Face a 2027 Net Metering Reset Ahead

Updated Category News Views 72

A policy switch buried in a Dutch calendar is about to rearrange millions of kitchen-table energy calculations. On 1 January 2027, the Netherlands ends net metering, or salderingsregeling, and households with solar panels will no longer offset exported power against electricity bought from the grid. That is not some abstract regulatory footnote. It changes the value of...

Continue Reading
Mudrick Urges Doncasters to Test a Strategic Sale Now

Updated Category News Views 36

Castings are rarely glamorous until nobody can get them, and Mudrick Capital is betting that ugly little industrial reality could make Doncasters worth far more in a takeover than the market currently credits. The event-driven investor, which says it owns roughly 4.3% of DPC Holdings Limited, has asked the board to quietly evaluate strategic alternatives, including a sale...

Continue Reading

Top 5 Most Recently Viewed Articles

A.O. Smith Sells 81% of China Arm to CPE: Key Takeaways

Updated Category News Views 372

When a major player like A.O. Smith decides to offload a piece of its business, folks tend to sit up and pay attention. This isn't just some run-of-the-mill shuffling. A.O. Smith has inked a deal with CPE to hand over an 81% stake in its China business. What does this transaction bring to the table and who stands to gain? Broken Down for the Curious Investor The numbers...

Continue Reading
NCCN Expands Global Influence at Historical Cancer Forum

Updated Category News Views 177

NCCN’s Involvement in Global Cancer Initiatives The National Comprehensive Cancer Network is actively participating in a progressive forum uniting various organizations dedicated to cancer control. This gathering includes representatives from approximately 75 nations, marking a significant milestone in international collaboration. Focus of the Cancer Planners Forum The...

Continue Reading
eGlint's Rapid Tech Revolutionizes Proteomics with Win

Updated Category News Views 85

A Game-Changer in Proteomics Now ain't this something—eGlint just scooped up the 2026 BioTools Innovator Grand Prize, waving a big ol' $250,000 check around and claiming the biotech spotlight with their swift-moving ProteoNex™ platform. Forget about sticking samples through sluggish labs and waiting an eternity; eGlint's tech is flipping the switch, serving up protein...

Continue Reading
Exploring the Surge in Options Trading with GE Vernova Insights

Updated Category News Views 67

Understanding the Current Options Trading Landscape of GE Vernova Recently, financial sectors have shown strong bullish interest in GE Vernova. Our detailed analysis indicates a noteworthy trend in options trading for GE Vernova (GEV), where we've identified an impressive number of unusual trading activities. Digging deeper into the specifics, we observed that 66% of...

Continue Reading
Volatus Aerospace: Leading the Charge in Aerial Innovations

Updated Category News Views 310

Volatus Aerospace: Leading the Charge in Aerial Innovations Volatus Aerospace Inc. (TSXV: FLT, OTCQX: TAKOF, Frankfurt: ABB) continues to excel as a frontrunner in sovereign aerial solutions. The company recently shared an impressive corporate update, showcasing its robust financial standing, an increasing array of international contracts, and a commitment to align with...

Continue Reading